Search the Newsreel

Gilead Sciences: A Strong Quarter Hidden Behind A Bottom-Line Loss (NASDAQ:GILD)

Scotiabank Predicts Stronger Earnings for Gildan Activewear

Ermenegildo Zegna (NYSE:ZGN) Hits New 12-Month High - Still a Buy?

Stockholder Alert: Robbins LLP Informs Investors of the Gildan Activewear Inc. Class Action

Robbins LLP has filed a securities class action lawsuit on behalf of former HanesBrands shareholders who acquired Gildan Activewear Inc. (NYSE/TSE: GIL) shares during the December 2025 cash-and-stock exchange. The lawsuit alleges that Gildan's Offering Materials contained materially false or misleading statements, specifically regarding …

Stronger First-Half 2026 Revenues Might Change The Case For Investing In Ermenegildo Zegna (ZGN)

Ermenegildo Zegna (ZGN) reported robust revenue growth for Q2 and the first half of 2026, with total revenues of €517.1 million and €987.3 million respectively, indicating sustained customer demand for its luxury brands. While this growth supports the company's investment narrative, challenges such as …

Amundi Makes New Investment in Ermenegildo Zegna N.V. $ZGN

Amundi has made a new investment in Ermenegildo Zegna N.V. (NYSE:ZGN), acquiring over 1 million shares valued at approximately $10.7 million. This move adds to institutional ownership, which collectively stands at 12.91% of the company's stock. The article also notes recent analyst ratings, with …

Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors

Gilead Sciences Inc. (GILD) stock fell 2.58% to $131.76 on Wednesday, underperforming compared to its competitors and ending a two-day winning streak. This occurred on a mixed trading day where the Dow Jones Industrial Average rose, but the S&P 500 Index declined.

Arcus Biosciences (NYSE: RCUS) posts Q2 loss, ends Gilead options

Arcus Biosciences reported a Q2 2026 net loss of $91 million, or $0.72 per share, with total revenues of $41 million, a significant decrease from $160 million in Q2 2025 due to the absence of a large one-time payment from Gilead. Broad Gilead option …

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend. Continue Reading

Gildan Investor News: If You Have Suffered Losses in Gildan

The Rosen Law Firm is investigating potential securities claims against Gildan Activewear Inc. (NYSE: GIL) following a short seller report by Jehoshaphat Research. The report questioned Gildan's organic growth and sales practices, causing Gildan's NYSE shares to fall by 18.7% on June 16, 2026. …

Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AIDS Healthcare Foundation publicly criticizes Gilead Sciences on its global HIV drug pricing and access policies. The advocacy group alleges that Gilead benefits from taxpayer-funded research while …

Gilead Sciences Inc Stock (GILD) Moved Down by 3.96% on Aug 5: A Full Analysis

Gilead Sciences Inc (GILD) stock dropped by 3.96% on August 5th following a downward revision of its full-year earnings guidance. This decline is attributed to decelerating sales in its core HIV franchise, disappointing clinical trial results in oncology, and increased operational and research costs. …

Gilead Sciences (GILD) Faces Fresh HIV Access Criticism From AIDS Healthcare Foundation

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AIDS Healthcare Foundation publicly criticizes Gilead Sciences on its global HIV drug pricing and access policies. The advocacy group alleges that Gilead benefits from taxpayer-funded research while …

The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth

In early August 2026, Gilead Sciences reported second-quarter revenue of US$7.80 billion but moved to a quarterly net loss of US$10.50 billion, widened its full-year 2026 loss guidance, and still affirmed a US$0.82 per-share dividend while continuing selective share repurchases. Despite the reported loss …

Renaissance Technologies LLC Sells 45,500 Shares of Gildan Activewear, Inc. $GIL

Renaissance Technologies LLC decreased its stake in Gildan Activewear, Inc. by 26.8% in the first quarter of 2026, selling 45,500 shares and retaining 124,552 shares valued at $6.9 million. Despite this, Gildan reported strong quarterly earnings of $1.28 per share, surpassing estimates, and revenue …

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026

Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026 Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 10.2% year on year to $7.80 billion. On the other hand, the company's full-year revenue guidance of …

GIL Legal News: Gildan Hit with Securities Fraud

Bleichmar Fonti & Auld LLP is investigating Gildan Activewear Inc. (NYSE:GIL) for potential securities fraud. This follows a significant stock drop after a report alleged Gildan engaged in a "channel stuffing" scheme to inflate revenue. Investors who experienced losses are encouraged to contact BFA …

Gilead Raised HIV Guidance on Its Q2 Earnings Call. Here’s What That Means for GILD Stock.

Gilead Sciences Announces Second Quarter 2026 Financial Results

Gilead Sciences announced its second quarter 2026 financial results, reporting a 10% year-over-year revenue growth in its base business, driven by its HIV portfolio, Trodelvy, and Livdelzi. The company reported diluted loss per share of $(8.45) and non-GAAP diluted loss per share of $(6.75), …

California High Court’s Gilead Ruling Marks Tort Law Sea Change

The California Supreme Court has issued a landmark ruling shielding Gilead Sciences Inc. from liability related to developing and marketing its drugs, even if safer alternatives exist within its pipeline. This decision, described as a "monumental shift," provides an exception from the duty of …

Gilead Sciences Inc (GILD) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Gilead Sciences (GILD) Stock Price Reflects R And D Shock Not Sales Weakness

Gilead's Steady Long-Term Growth Prospects in HIV and Expansion in Oncology Support a Wide Moat

Gilead Sciences maintains a wide economic moat due to strong profit margins from its HIV and hepatitis C virus portfolios. The company's future growth relies on continued innovation in HIV, successful oncology product launches, and strategic acquisitions. These factors are expected to drive mid-single-digit …

Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...

This article first appeared on GuruFocus. Total Product Sales (excluding Veklury): $7.6 billion, up 10% year-over-year. Total Product Sales (including Veklury): $7.6 billion, up 8% year-over-year. HIV Sales: $5.7 billion, up 12% year-over-year. Biktarvy Sales: $3.8 billion, up 7% year-over-year. PrEP Business Sales: Exceeded …

Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury drop

[ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha MORE ON GILEAD SCIENCES * Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript [https://seekingalpha.com/article/4930335-gilead-sciences-inc-gild-q2-2026-earnings-call-transcript] * Gilead Sciences, Inc. 2026 Q2 - Results - …

Gildan Activewear Inc. Price Target Cut to $57.00/Share From $69.00 by Citi

Citi has lowered its price target for Gildan Activewear Inc. (GIL) shares to $57.00 from $69.00, while maintaining a "Buy" rating on the stock. This adjustment reflects a re-evaluation by the firm but still indicates a positive outlook on the company's future performance. The …

CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results

Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion Diluted Loss Per Share was $(8.45) and Non-GAAP Diluted Loss Per Share was $(6.75) Reflecting $(9.08) Per Share Acquired IPR&D and Tax Expenses Associated with Recent …

Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10%

Earnings Call Insights: Gilead Sciences (GILD) Q2 2026 MANAGEMENT VIEW * "Gilead has delivered another quarter of commercial excellence with base business sales up 10% year-over-year... driven by our HIV portfolio, Trodelvy and Livdelzi," said (Chairman & CEO Daniel O'Day), adding that "we are …

Gilead Sciences Q2 Earnings Call Highlights

Key Points Interested in Gilead Sciences, Inc.? Here are five stocks we like better. Base business sales rose 10% year over year to $7.6 billion, led by HIV, oncology and liver treatments. Gilead raised its full-year base business sales outlook to $29.8 billion–$30.1 billion …

Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Gilead Sciences (GILD) reported revenue of $7.8 billion, up 10.2% over the same period last year. EPS came in at -$6.75, compared to $2.01 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of …

Gilead’s PrEP Business Hits Billion-Dollar Sales Mark

Gilead Sciences announced its second-quarter 2026 financial results, revealing that its PrEP (Pre-Exposure Prophylaxis) business has reached billion-dollar sales. The article highlights Gilead's financial performance and success in the commercial strategy for its infectious disease portfolio.

Informe de resultados: Gilead supera previsiones del Q2 2026

Gilead's High-Profile HIV Drug Beat, But That's Not What Grabbed Attention

Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock edged lower late, still in a downtrend. Continue Reading

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Gilead Sciences (GILD) came out with a quarterly loss of $6.75 per share versus the Zacks Consensus Estimate of a loss of $7.07. This compares to earnings of $2.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report …

Gilead Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:GILD) 2026-08-04

This article provides details of Gilead Sciences, Inc.'s Q2 2026 earnings call presentation. The company reported an EPS of -$6.75, beating estimates by $0.50, and revenue of $7.80 billion, a 10.18% year-over-year increase, beating estimates by $400.50 million. The information is based on the …

AHF Crowns Gilead Corporate Welfare King

LOS ANGELES, August 04, 2026--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) condemns Gilead Sciences' greed as the drug company giant gloats over its latest quarterly financial results. The only thing new is the numbers detailing the parasitic profits from one of the worst epidemics to hit …